Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1995 Jun;63(6):2141-6.
doi: 10.1128/iai.63.6.2141-2146.1995.

A toxic shock syndrome toxin 1 mutant that defines a functional site critical for T-cell activation

Affiliations

A toxic shock syndrome toxin 1 mutant that defines a functional site critical for T-cell activation

C M Cullen et al. Infect Immun. 1995 Jun.

Abstract

Toxic shock syndrome toxin 1 (TSST-1), a superantigen produced by Staphylococcus aureus, is a causative agent of toxic shock syndrome (TSS). This superantigen is a potent stimulator of T cells and macrophages/monocytes, resulting in the release of cytokines that are implicated in the pathogenesis of TSS. This study characterizes a mutant TSST-1, derived by site-directed mutagenesis, that has an alanine substitution at histidine 135 (mutant 135). This single-amino-acid change results in a mutant toxin that has lost mitogenic activity for T cells. In contrast to wild-type TSST-1, this mutant does not induce T cells to express interleukin-2, gamma interferon, or tumor necrosis factor beta (TNF-beta). The inability of mutant 135 to activate T cells is not due to a lack of binding to the class II major histocompatibility complex receptor. In addition, the mutant TSST-1 does not induce expression of TNF-alpha, which plays a role in the development of lethal shock. The lack of TNF-alpha induction by mutant 135 is likely due to its inability to activate T cells. These data suggest that the mutation at histidine 135 in TSST-1 affects toxin interactions with the T-cell receptor rather than the class II major histocompatibility complex receptor.

PubMed Disclaimer

References

    1. J Immunol. 1994 Dec 1;153(11):4853-61 - PubMed
    1. Nature. 1994 Apr 21;368(6473):711-8 - PubMed
    1. J Immunol. 1979 Jun;122(6):2491-7 - PubMed
    1. Lancet. 1981 May 9;1(8228):1017-21 - PubMed
    1. J Infect Dis. 1981 Apr;143(4):509-16 - PubMed

Publication types

LinkOut - more resources